All lobbying filings

The McManus Group

The McManus Group filed a Q2 report for Venture Medical on July 20, 2026, reporting $30,000 in lobbying income.

Lobbying for Venture Medical · Provider of Innovative Solutions in Wound Healing and Regenerative Therapies

As filed: THE MCMANUS GROUP for VENTURE MEDICAL.

All filings by The McManus Group · Everything Venture Medical has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$30,000

What the client paid this registrant for the period.

Client based in

Montana

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F).

Bills named in this filing 3

H.R. 5768
Skin Substitute Access and Payment Reform Act
S. 2561
Skin Substitute Access and Payment Reform Act of 2025
H.R. 6852
Advanced Wound Care and Regenerative Medicine Access and Reform Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.